CA Patent

CA3172752A1 — Novel formulation of bis-choline tetrathiomolybdate for treating copper metabolism-associated diseases or disorders

Assigned to Alexion Pharmaceuticals Inc · Expires 2022-08-04 · 4y expired

What this patent protects

This disclosure relates to novel formulations of bis-choline tetrathiomolybdate useful for treating a copper metabolism-associated disease or disorder, such as Wilson disease (WD). For example, this disclosure relates to low dose formulations of bis-choline tetrathiomolybdate.

USPTO Abstract

This disclosure relates to novel formulations of bis-choline tetrathiomolybdate useful for treating a copper metabolism-associated disease or disorder, such as Wilson disease (WD). For example, this disclosure relates to low dose formulations of bis-choline tetrathiomolybdate.

Drugs covered by this patent

Patent Metadata

Patent number
CA3172752A1
Jurisdiction
CA
Classification
—
Expires
2022-08-04
Drug substance claim
No
Drug product claim
No
Assignee
Alexion Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.